货号:A214046
同义名:
盐酸贝尼地平
/ KW-3049; Benidipine (hydrochloride)
Benidipine HCl 是一种二氢吡啶类钙通道拮抗剂,兼具抗氧化特性,可改善高血压大鼠冠状动脉循环,常用于高血压研究。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Ca2+ channel-like protein ↓ ↑ | Calcium Channel ↓ ↑ | Cav 2.2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC25B-IN-2 | ✔ | Akt | 99%+ | ||||||||||||||||
| Clevidipine | ✔ | 97% | |||||||||||||||||
| Verapamil HCl | ✔ | 99% | |||||||||||||||||
| Amlodipine | ✔ | 99% | |||||||||||||||||
| Amlodipine maleate | ✔ | 98% | |||||||||||||||||
| (+)-cis-Diltiazem HCl | ✔ | 99% | |||||||||||||||||
| Zegocractin |
++
Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM |
99%+ | |||||||||||||||||
| Tanshinone IIA sulfonate sodium | ✔ | 98% | |||||||||||||||||
| Ulixacaltamide |
++
hCaV3.2, IC50: 110 nM hCaV3.1, IC50: 50 nM |
99%+ | |||||||||||||||||
| Dronedarone HCl | ✔ | 95% | |||||||||||||||||
| Nitrendipine |
+
Calcium channel, IC50: 95 nM |
98% | |||||||||||||||||
| Efonidipine HCl monoethanolate | ✔ | 98% | |||||||||||||||||
| Cinnarizine | ✔ | 98% | |||||||||||||||||
| SEA0400 |
++
NCX, IC50: 33 nM |
ROS,ERK,p38 MAPK | 99%+ | ||||||||||||||||
| Fasudil HCl | ✔ | Rho,PKA | 98% | ||||||||||||||||
| ML-9 | ✔ | MLCK,Akt | 99%+ | ||||||||||||||||
| Flunarizine 2HCl |
+
Calcium channel, Ki: 68 nM |
95% | |||||||||||||||||
| Lomerizine 2HCl | ✔ | 98% | |||||||||||||||||
| Efonidipine | ✔ | 98% | |||||||||||||||||
| Levamlodipine | ✔ | 98% | |||||||||||||||||
| Nisoldipine |
++
L-type Cav1.2, IC50: 10 nM |
97% | |||||||||||||||||
| Isradipine | ✔ | 98% | |||||||||||||||||
| Lacidipine | ✔ | 98% | |||||||||||||||||
| Lercanidipine | ✔ | 99% | |||||||||||||||||
| Loureirin B | ✔ | Potassium Channel | 99%+ | ||||||||||||||||
| Tetracaine HCl | ✔ | 98% | |||||||||||||||||
| Manidipine |
+++
Calcium channel, IC50: 2.6 nM |
99% | |||||||||||||||||
| Manidipine Dihydrochlorid |
+++
Calcium channel, IC50: 2.6 nM |
98% | |||||||||||||||||
| Nicardipine | ✔ | 99% | |||||||||||||||||
| Wilforgine | ✔ | 98+% | |||||||||||||||||
| Econazole | ✔ | 99%+ | |||||||||||||||||
| Ginsenoside Rd | ✔ | NF-κB | 98% | ||||||||||||||||
| Fendiline HCl | ✔ | 98+% | |||||||||||||||||
| Mesaconitine | ✔ | 98% | |||||||||||||||||
| Tetrandrine | ✔ | 95% | |||||||||||||||||
| Nifedipine | ✔ | 98% | |||||||||||||||||
| Nilvadipine |
++++
Calcium channel, IC50: 0.03 nM |
95% | |||||||||||||||||
| Barnidipine |
++++
[3H]nitrendipine, Ki: 0.21 nM |
95+% | |||||||||||||||||
| Azelnidipine | ✔ | 97% | |||||||||||||||||
| Levetiracetam | ✔ | 98% | |||||||||||||||||
| Nimodipine | ✔ | 95% | |||||||||||||||||
| Benidipine HCl | ✔ | 98% | |||||||||||||||||
| Pinaverium bromide | ✔ | 98% | |||||||||||||||||
| Pranidipine | ✔ | 99% | |||||||||||||||||
| NP118809 |
+
N-type Ca2+ channel, IC50: 0.11 μM L-type calcium channel, IC50: 12.2 μM |
95% | |||||||||||||||||
| Amlodipine Besylate |
+++
Calcium channel, IC50: 1.9 nM |
97% | |||||||||||||||||
| Cilnidipine | ✔ | 99% | |||||||||||||||||
| Cinepazide Maleate | ✔ | 99% (HPLC) | |||||||||||||||||
| Terfenadine | ✔ | 98% | |||||||||||||||||
| YM-58483 | ✔ | 99%+ | |||||||||||||||||
| Amiloride HCl | ✔ | 98% | |||||||||||||||||
| Ranolazine | ✔ | 98% | |||||||||||||||||
| Praeruptorin A | ✔ | p38 MAPK,Akt | 98% | ||||||||||||||||
| Ranolazine 2HCl | ✔ | 98% | |||||||||||||||||
| Felodipine |
++++
L-type calcium channel, IC50: 0.15 nM |
98% | |||||||||||||||||
| PD173212 |
+++
N-type Ca2+ channel, IC50: 36 nM |
98% | |||||||||||||||||
| Levamlodipine besylate | ✔ | 97% | |||||||||||||||||
| Carboxyamidotriazole Orotate | ✔ | 98% | |||||||||||||||||
| IGS-1.76 | ✔ | 98+% | |||||||||||||||||
| WH-4-023 |
++++
Cav 2.2, IC50: 0.001 μM |
++++
Cav 2.2, IC50: 0.001 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Benidipine hydrochloride, a calcium channel blocker (CCB), inhibited SFTSV (Severe fever with thrombocytopenia syndrome virus) replication in vitro. Benidipine hydrochloride was revealed to inhibit virus infection through impairing virus internalization and genome replication[3]. Histopathologically neuroprotective effects of benidipine hydrochloride was seen in the cerebral cortex tissues. Benidipine hydrochloride can play a certain protective role in the cerebral I/R injury. The protective effect of this agent may be related to the improvement on the antioxidant capacity of brain tissue and the inhibition of overproduction of inflammatory cytokines[4]. Moreover, patients with hypertension have high plasma TBARS (thiobarbituric acid reactive substance), and benidipine hydrochloride decreases not only blood pressure but also oxidative stress in the clinical practice[5]. Benidipine has a more potent antihypertensive effect than cilnidipine and also a renoprotective effect, indicating the high usefulness of benidipine in hypertensive patients with diabetes[6]. Combination therapy with benidipine hydrochloride and candesartan cilexetil may contribute to the suppression of arteriosclerosis and may be useful for elderly hypertensive patients with diabetes mellitus[7]. |
| Concentration | Treated Time | Description | References | |
| GE1 cells | 1, 10, 100, 1000, 10000 nM | 12 hours | Promoted GE1 cell proliferation | Adv Wound Care (New Rochelle). 2019 Mar 1;8(3):108-117. |
| MC3T3-E1 cells | 0.01, 0.10, 1.00 µM | 21 days | To evaluate the effect of Benidipine on matrix mineralization in MC3T3-E1 cells, results showed that Benidipine significantly promoted extracellular matrix mineralization. | J Zhejiang Univ Sci B. 2021 May 15;22(5):410-420. |
| MLO-Y4 cells | 0.1, 1, 10, 100, 1000, 10000 nM | 24 hours | Promoted MLO-Y4 cell proliferation | Adv Wound Care (New Rochelle). 2019 Mar 1;8(3):108-117. |
| Huh7 cells | 10 µM | 24 hours | Benidipine HCl significantly inhibited HTNV replication in Huh7 cells | Front Pharmacol. 2022 Aug 29;13:940178. |
| A549 cells | 6.552 µM | 24 hours | Benidipine HCl significantly inhibited HTNV replication in A549 cells with an IC50 of 6.552 μM | Front Pharmacol. 2022 Aug 29;13:940178. |
| Rat aortic endothelial cells | 10 nM | 30 minutes | To investigate the effects of benidipine on LPC-induced suppression of [Ca2+]i increase in endothelial cells, results showed that benidipine inhibited LPC-induced suppression of [Ca2+]i increase | J Biomed Sci. 2009 Jun 26;16(1):57. |
| Vero cells | 10 µM | 36 hours | Benidipine hydrochloride showed the strongest inhibitory effect on SFTSV infection (>90%) at the concentration of 10 μM. | Cell Res. 2019 Sep;29(9):739-753. |
| HEK293T cells | 1 µM | 40 minutes | To investigate the inhibitory mechanism of Benidipine on CaV1.2 channels, cryo-EM structural analysis revealed that Benidipine is located in the DIII-DIV fenestration site, and its hydrophobic sidechain provides additional interactions with the channel subunit α1, supporting its inhibitory effects on both L-type and T-type voltage-gated calcium channels | Nat Commun. 2024 Mar 30;15(1):2772. |
| MC3T3-E1 cells | 0.01, 0.10, 1.00 µM | 48 hours | To evaluate the effect of Benidipine on the proliferation of MC3T3-E1 cells, results showed that Benidipine significantly promoted cell proliferation in a dose-dependent manner. | J Zhejiang Univ Sci B. 2021 May 15;22(5):410-420. |
| MC3T3-E1 cells | 0.01, 0.10, 1.00 µM | 7, 10, 14 days | To evaluate the effect of Benidipine on alkaline phosphatase (ALP) activity in MC3T3-E1 cells, results showed that Benidipine significantly increased ALP activity, especially at 10 and 14 days. | J Zhejiang Univ Sci B. 2021 May 15;22(5):410-420. |
| MRC5 normal human fibroblasts | 10 µM | Benidipine selectively promotes the death of cigarette smoke-induced senescent lung cells | Aging (Albany NY). 2023 Dec 12;15(23):13581-13592. | |
| Administration | Dosage | Frequency | Description | References | ||
| Wistar rats | MRONJ-like lesion model | Local injection | 0.13 mg/kg, 1.3 mg/kg | Single injection, lasting two weeks | Promote healing of MRONJ-like lesions, reduce necrotic bone area, and promote new bone formation | Pharmaceuticals (Basel). 2022 Aug 18;15(8):1020 |
| Sprague-Dawley rats | Myocardial ischemia/reperfusion model | Intravenous injection | 10 mg/kg | Single dose, 10 minutes before reperfusion | Benidipine exerts its antiapoptotic effect by inhibiting the mitochondrial-mediated apoptotic pathway (but not the death receptor-mediated pathway), reducing myocardial apoptosis. Specifically, it decreased TUNEL-positive staining (8.4±1.2% vs 15.3±1.3%), reduced caspase-3 activity (1.94±0.25 vs 3.43±0.29), and inhibited mitochondrial cytochrome c release and caspase-9 activation. Additionally, benidipine enhanced ERK1/2 activity and prolonged its activation duration but had no significant effect on p38 MAPK. | Br J Pharmacol. 2004 Jun;142(4):627-34 |
| C57BL/6 mice | SFTSV infection model | Intragastric administration | 15 mg/kg | Twice a day for 7 days | Benidipine hydrochloride and nifedipine significantly reduced viral loads in spleen and serum, and alleviated SFTSV-induced pathogenesis. | Cell Res. 2019 Sep;29(9):739-753. |
| Rats | Tooth extraction socket model | Local injection | 15 or 45 μg/kg | Single injection, lasting 28 days | Evaluated the effect of BD on bone and gingival healing at the extraction socket. Results showed BD significantly augmented bone volume and density, and also promoted epithelial wound healing. | Adv Wound Care (New Rochelle). 2019 Mar 1;8(3):108-117. |
| New Zealand white rabbits | Myocardial ischemia/reperfusion model | Intravenous injection | 3 mg/kg or 10 mg/kg | Single dose, observed for 4 hours and 45 minutes | To investigate the effects of benidipine on myocardial infarct size, apoptosis, necrosis, and cardiac functional recovery in rabbits subjected to myocardial ischemia/reperfusion. Results showed that 10 mg/kg benidipine significantly reduced myocardial apoptosis (6.2 ±0.8% vs 12.2 ±1.1%), necrosis, and infarct size (20 ±2.3% vs 49 ±2.6%), and improved cardiac functional recovery. 3 mg/kg benidipine, without hemodynamic effects, still significantly reduced apoptosis but failed to reduce necrosis. | Br J Pharmacol. 2001 Feb;132(4):869-78 |
| Sprague-Dawley rats | Sprague-Dawley rats | Oral | 4 mg/kg | Single dose, aortas were isolated 90 minutes after administration | To investigate the protective effects of benidipine on LPC-induced impairment of endothelium-dependent relaxation, results showed that benidipine inhibited LPC-induced endothelial dysfunction | J Biomed Sci. 2009 Jun 26;16(1):57. |
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00135551 | Cardiovascular Disease | Phase 4 | Completed | - | Japan ... 展开 >> Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine Ube, Yamaguchi, Japan, 755-8505 收起 << |
| NCT02646397 | Chronic Kidney Disease | Phase 4 | Unknown | December 2017 | China, Shanghai ... 展开 >> Department of Nephrology, Shanghai Changzheng Hospital Shanghai, Shanghai, China, 200003 收起 << |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.84mL 0.37mL 0.18mL |
9.22mL 1.84mL 0.92mL |
18.45mL 3.69mL 1.84mL |
|
| CAS号 | 91599-74-5 |
| 分子式 | C28H32ClN3O6 |
| 分子量 | 542.02 |
| SMILES Code | O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)O[C@H]3CN(CC4=CC=CC=C4)CCC3.[H]Cl |
| MDL No. | MFCD06407650 |
| 别名 | 盐酸贝尼地平 ;KW-3049; Benidipine (hydrochloride); (±)-Benidipine; Benidipine hydrochloride |
| 运输 | 蓝冰 |
| InChI Key | KILKDKRQBYMKQX-MIPPOABVSA-N |
| Pubchem ID | 656667 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 35 mg/mL(64.57 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1